Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Aug 2026 to May 27, 2026
    • Eligibility criteria expanded, about 26 words
    • Secondary endpoints: details revised at 14 of 18 entries
    • Publications: details revised at 1 of 1 entry
  2. Primary completion date: Mar 2026 to Aug 2026
    • Study completion date: Mar 2029 to Aug 2029
    v10
  3. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 50 to confirmed 47
    • Site details revised at 4 of 4 sites
    v9
  4. Study sites: 3 to 4
    • Primary completion date: Jan 8, 2026 to Mar 2026
    • Study completion date: Jan 8, 2029 to Mar 2029
    v8
  5. Study sites: 2 to 3v7
Show 5 earlier versionsHide 5 earlier versions
  1. Re-verified, no change to tracked fieldsv6
  2. Study sites: 1 to 2v5
  3. Re-verified, no change to tracked fieldsv4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 2023 to Jul 18, 2023
    • Site details revised
    v3
  5. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine how effective and safe the combination of glofitamab and obinutuzumab is in treating patients with Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) who have not received other treatments for their lymphoma. The names of the study drugs involved in this study are: * Glofitamab (a type of immunotherapy) * Obinutuzumab (a type of immunotherapy)
Trial Details
NCT Number NCT05783596
Lead Sponsor Reid Merryman, MD
Collaborators: Genentech, Inc.
Conditions
(from sponsor)		 Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma
Related terms Lymphoma, B-Cell, Marginal Zone, Lymphoma, Follicular
Enrollment 47 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov